提醒

提醒专业图表

Standard BioTools Inc. (LAB)

NasdaqGS: LAB · 实时价格 · USD

0.79

+0.00 (0.00%)

收盘价： Aug 12, 2026, 3:59 PM

0.79

+0.00%

盘后: 4:10 PM

0.00% (1D)

买价	0.55
市值	311.75M
营收（TTM）	84.6M
净利润（TTM）	-53.93M
贝塔值	n/a
每股收益（TTM）	-0.13
市盈率（TTM）	n/a
预期市盈率	-79.41
市净率（TTM）	0.58
市销率（TTM）	3.69
Earnings Date	Nov 3, 2026

卖价	1
成交量	1,013,036
20日均量	3,434,572
开盘价	0.77
前收盘价	0.79
日内区间	0.77 - 0.80
52周区间	0.70 - 1.72
分析师	Hold
目标价	1.35 (70.89%)
分红	n/a
除息日	n/a

关于 LAB

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses....

[阅读更多]

行业 Medical Devices

板块 Healthcare

上市日期 Feb 10, 2011

员工人数 385

交易所 NasdaqGS

股票代码 LAB

官网 https://www.standardbio.com

公司完整简介

财务表现

2025年，Standard BioTools的营收为85.33M，较上一年的91.01M下降-6.24%。净利润为-74.9M，下降-46.07%。

财务报表

分析师预测

根据1位分析师的评级，LAB的平均评级为“Hold”。12个月目标价为1.35，较最新价格上涨空间70.89%。

股票预测

财报意外

Standard BioTools 已于 Aug 5, 2026 发布季度财报：

营收为 $20.1M 低于预期 $0, ， -7.62% 同比下滑.

每股收益为 -0.06 低于预期 -0.03, ， -50.00% 同比下滑.

下次财报发布时间

Standard BioTools Inc. 计划于以下时间发布财报 Nov 3, 2026, 盘中。
分析师预计营收为 ... 升级

新闻

2周前 · MT Newswires

Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences

Standard BioTools (LAB) said Tuesday that it has agreed to sell its Mass Cytometry business to Multi

2月前 · BioPharma Dive

Stealthy startup Treeline plans a reverse merger

Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

3月前 · Zacks

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools (LAB) delivered earnings and revenue surprises of 0.00% and +13.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

4月前 · Insider Monkey

Standard BioTools (LAB) is One of the Best Life Sciences Penny Stocks, Here is Why

Standard BioTools Inc. (NASDAQ:LAB) is one of the 8 Best Life Sciences Penny Stocks to Buy. As of the April 8 close, Standard BioTools Inc. (NASDAQ:LAB) had a neutral consensus sentiment. The stock re...

5月前 · Motley Fool

Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.

第 1 页，共 2 页

Standard BioTools Inc. (LAB)